TM6SF2’s role in reducing VLDL secretion contributes to hepatocyte lipid accumulation, a recognized trigger of unfolded protein response pathways in MASLD pathogenesis [14,15]. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.